City of Research proud of volunteers involvement as Novavax COVID-19 vaccine is found to be 89.3% effective

The City of Research supported Novavax COVID-19 vaccine is 89.3% effective at preventing COVID-19, shown from interim analysis of its Phase III study data, including effectiveness against the new variants of concern.

The Novavax study was the first Phase III study of the Vovavax COVID-19 vaccine in the world.  The study was also the largest ever double blind, placebo-controlled trial ever undertaken in the UK. 15,000 participants recruited in just two months including those selected from over 4000 who signed up to be Research Volunteers from Bradford City Region. This was a fantastic example of the vital role that City of Research partners played, together with its National network partners, to rapidly recruit and enrol volunteers.  

Professor Dinesh Saralaya, Director of the NIHR Patient Recruitment Centre Bradford said that the Research Volunteers could be “proud at being part of a world race to find an effective vaccine against Covid-19.”

The Novavax jab is also the first to show in trials that it is effective against the new virus variant found in the UK and Clive Dix, Chair, UK Vaccine Taskforce, said that “The efficacy shown against the emerging variants is extremely encouraging. This is an incredible achievement that will ensure we can protect individuals in the UK and the rest of the world from this virus.”

You can find out more and volunteer for future vaccine studies by visiting

The UK government has already secured 60 million doses of the Novavax NVX-CoV2373 vaccine. Provided it meets standards on safety, effectiveness and quality following publication of results, the vaccine will be manufactured using FUJIFILM Diosynth Biotechnologies’s facilities in Billingham, Stockton-on-Tees.